Xenetic Biosciences, Inc. · NASDAQ:XBIO
Xenetic Biosciences — Investor Presentation (June 2023)
30 slides from Xenetic Biosciences's investor presentation, Jun 6, 2023
Slide 1: Corporate Presentation June 2023
nasdaq : XBIO xeneticbio.com Corporate Presentation June 2023
Slide 2: Forward-looking statements
This presentation contains forward - looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation other than statements of historical facts may constitute forward - looking statem
Slide 3: Investment Highlights
Investment Highlights 3 Focused on advancing proprietary technology platform to address multiple high - value cancer indications DNase I Oncology Platform Aimed at improving immunotherapies by targeting Neutrophil Extracellular Traps (NETs) DNase I – Our Innovative Solution DNase I is an enzyme that
Slide 4: Innovative Oncology Pipeline
4 Innovative Oncology Pipeline Opportunity to Address Multiple Oncology Indications DNase I HIGHLIGHTS PHASE 2 PHASE 1 IND ENABLING PRECLINICAL INDICATIONS TECHNOLOGY PROGRAM Upcoming study to evaluate combination with chemo Pancreatic Carcinoma Systemic DNase I (+Chemo) XBIO - 015 Upcoming study to
Slide 5: Leveraging DNase I to Target Neutrophil Extracellular Traps (NETs)
Leveraging DNase I to Target Neutrophil Extracellular Traps (NETs) 5
Slide 6: The Role of Neutrophil Extracellular Traps (NETs)
The Role of Neutrophil Extracellular Traps (NETs) 6 NETs are an Innate Immune Response to Kill Invading Pathogens NETs are composed of cell - free DNA, histones, neutrophil elastase, MMP - 9 and other proteins Neutrophil Cancer Cells Cancer Cells Caught in NET Elevated levels of NETs lead to inflamm
Slide 7: Role of NETs in Cancer Progression
Role of NETs in Cancer Progression 7 Primary Tumor Microenvironment NETs Neutrophil Secondary Metastatic Tumor Epithelial - Mesenchymal Transition (EMT) of primary tumor cells Circulating tumor cells are shielded by NETs, preventing attack by the immune system NETs can potentiate the establishment o
Slide 8: NETs Can Limit the Effectiveness of Current Cancer Therapies
NETs Can Limit the Effectiveness of Current Cancer Therapies 8 Shaping of the Tumor Microenvironment (TME) Engaging in Pro - tumorigenic and Immunosuppressive Signaling, thereby Promoting Cancer Cell Proliferation, Invasion and Metastasis Promoting Hypercoagulability and Treatment - Associated Throm
Slide 9: Neutrophil Extracellular Traps publications
Neutrophils Extracellular Traps Inhibition Improves PD - 1 Blockade Immunotherapy in Colorectal Cancer Hongji Zhang, Yu Wang, Amblessed Onuma , Jiayi He, Han Wang, Yujia Xia, Rhea Lal 5, Xiang Cheng, Gyulnara Kasumova , Zhiwei Hu, Meihong Deng, Joal D. Beane, Alex C. Kim, Hai Huang, and Allan Tsung
Slide 10: Systemic DNase I Mode of Action
10 Systemic DNase I Mode of Action Primary Tumor Microenvironment NETs Neutrophil DNase I DNase I is an enzyme that digests DNA and can eliminate NETs thereby exposing cancer cells to the immune system, chemotherapy and other targeted cancer treatments Co - administered with Immune Checkpoint Inhibi
Slide 11: DNase I Has the Potential to Improve Current Cancer Therapies
DNase I Has the Potential to Improve Current Cancer Therapies 11 Overcome T cell exclusion and immunosuppressive signals by the tumor microenvironment (TME) Improve side effect profiles of current ChemoRx
Slide 12: DNase I Improves Efficacy of PD-Blockade
DNase I Improves Efficacy of PD - 1 Blockade 12 Combination of DNase I and anti - PD - 1 mAb resulted in the lowest tumor volume growth, superior to either DNase I or anti - PD - 1 alone Systemic administration of DNase I improves the efficacy of PD - 1 blockade to reduce the growth of cancer in MC3
Slide 13: DNase I Slowed Tumor Growth and Prolonged Survival
DNase I Slowed Tumor Growth and Prolonged Survival 13 Systemic Administration of DNase I and Anti - PD - 1 Resulted in the Slowest Tumor Growth and Prolonged Overall Survival in MC38 Colorectal Cancer Cell Model Overall Survival Control Anti - PD1 DNase I DNase I+Anti - PD - 1 100 Overall Survival (
Slide 14: DNase I for the Treatment of Pancreatic Carcinoma
DNase I for the Treatment of Pancreatic Carcinoma 14 Advancing Toward First - In - Human Study
Slide 15: Initially Targeting Pancreatic Carcinoma
Initially Targeting Pancreatic Carcinoma 15 Multi - Billion - Dollar Indication with Significant Unmet Need 5 - year survival for advanced stage patients: ~3% 1 Early detection is currently not feasible – most patients are diagnosed at advanced stages Deadliest Cancer in the United States 1 3 rd Dia
Slide 16: Currently Planned Phase 1 Study
Currently Planned Phase 1 Study 16 Multicenter, dose escalation and dose - expansion in subjects with locally advanced or metastatic solid tumors IV administration of rhDNase I Monotherapy dose escalation followed by expansion in two cohorts Combined with chemotherapy for pancreatic cancer patients
Slide 17: Key Drivers for Success
Key Drivers for Success 17 Pancreatic Cancer is a Challenging Indication but We Believe We Will Be Successful Relatively Low Hurdle for Demonstrating Clinical Meaningfulness ORR > 50% or PFS > 9 Months Would be Meaningful Improvement to Current SOC Ipsen’s NAPOLI - 3 Study 1 NALIRIFOX demonstrated 4
Slide 18: Application Across a Number of Solid Tumors
Application Across a Number of Solid Tumors 18 ~1.9 million new solid tumor cases in the U.S. in 2022 1 ~.6 million solid tumor related deaths in the U.S. in 2022 1 New Cases Annually 1 New Cases Annually 1 New Cases Annually 1 ~290K ~343K ~254K Breast Gastrointestinal Lung 1. 2022, American Cancer
Slide 19: DNase I Armored CAR T Targeting Solid Tumors
DNase I Armored CAR T 19 Targeting Solid Tumors Provides Opportunities for Significant Upside
Slide 20: DNase I Armored CAR T for Solid Tumors
20 DNase I Armored CAR T for Solid Tumors Requirements for Successful T Cell Therapies in Solid Tumors Find the tumor Infiltrate and persist in tumor Maintain cytotoxic function Barriers to Success in the Tumor Microenvironment Physical barriers (e.g., extracellular matrix or NETs) impeding infiltra
Slide 21: DNase I-Armored CAR T for Solid Tumors
21 DNase I - Armored CAR T for Solid Tumors Primary Tumor Microenvironment NETs DNase I CAR T CAR T cells that deliver DNase I while maintaining CAR T tumor killing function DNase I digests DNA, clearing NETs and allowing tumor access to CAR T
Slide 22: DNase I Armored CAR T: Proof of Concept
DNase I Armored CAR T: Proof of Concept 22 Ability to Design CAR T Cells That Deliver DNase I While Maintaining CAR T Function 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0 500000 1000000 1500000 2000000 [DNase I] (mg/L) # of CAR T cells DNase I levels in culture media anti - HER2 CAR T DNase I - armored ant
Slide 23: Advancing with Collaboration Partner, VolitionRX
Advancing with Collaboration Partner, VolitionRX 23 Developing Proprietary Adoptive Cell Therapies Potentially Targeting Multiple Solid Cancer Types DNase I - Armored CAR T Nu.Q ® Technology Expect Volition to fund research program and two parties to share proceeds from commercialization or licensin
Slide 24: Intellectual Property and Exclusivity
Intellectual Property and Exclusivity 24 Systemic DNase I DNase I - Armored CAR T IP Portfolio Co - administration of Systemic DNase I with ICIs, Radiation, Chemo Orphan Designation DNase I for pancreatic cancer IP Portfolio Co - administration of Systemic DNase I with CAR T DNase I - secreting CAR
Slide 25: Team with Proven Expertise
Team with Proven Expertise 25 Jeffrey F. Eisenberg Chief Executive Officer & Director Life Sciences executive with over 25 years of successful track record in value creation in both private and public companies; fo rmer CEO of Noven Pharmaceuticals, responsible for leading 2 product launches and Nov
Slide 26: Scientific Advisors
Dr. Allan Tsung Chair of the Department of Surgery at the University of Virginia School of Medicine and Director of the Cancer Therapeutics program at the University of Virginia Comprehensive Cancer Center; specializes in treating patients with liver, bile duct and pancreatic cancer Dr. Jonathan Spi
Slide 27: Financial Snapshot
Financial Snapshot NASDAQ: XBIO 27 Receiving royalties on net sales through licensing arrangement in the field of blood coagulation disorders from legacy assets Average Volume 2 Shares Outstanding 3 Market Cap 2 Cash Balance 1 ~23K ~1.5M ~$5M ~$12M 1. As of March 31, 2023 2. As of May 30, 2023, with
Slide 28: Key Upcoming Milestones
28 Key Upcoming Milestones 2024 - 2025 Activities 2022 - 2023 Activities Assets • Phase 1 study start x Engaged Catalent, preeminent CDMO for clinical manufacturing x IP supporting the use of DNase I in cancer • Dose escalation and expansion data available • Enhance preclinical data set x IND - enab
Slide 29: Investment Summary
Investment Summary 29 Advancing Proprietary Technology Platform Aimed at Improving Immunotherapies by Targeting Neutrophil Extracellular Traps (NETs) DNase I oncology platform has the potential to improve the efficacy of current cancer therapies Initially targeting pancreatic carcinoma, a multi - bi
Slide 30: Investor Relations
nasdaq : XBIO xeneticbio.com Investor Relations JTC Team 833 - 475 - 8247 xbio@jtcir.com
Xenetic Biosciences — Investor Presentation (June 2023) on 6ix